Navigation Links
Regado Biosciences, Inc. Presents Three Abstracts Pertaining to its Pipeline of Reversible Antithrombotic Agents, Including the Substudy Analyses of its Phase 2b RADAR Trial for REG1, its Lead Product Candidate, at the American Heart Association (AH
Date:11/14/2011

botics, uniquely concomitantly minimizing the risk of ischemia and bleeding, and, by allowing patient specific tuning of the desired therapeutic effect, providing a safe and unique approach to personalized medicine.

About REG1, REG2 and REG3

Regado's lead program, the anticoagulant system REG1, consists of two parenteral agents both administered by IV bolus, the first being a potent highly selective Factor IXa inhibitor (pegnivacogin, a.k.a. RB006) and the second being its complementary active control agent (anivamersen, a.k.a. RB007).  Anivamersen can be used to selectively completely or partially reverse the anticoagulant effect of pegnivacogin.  REG1, having recently completed phase 2b clinical development (the RADAR trial), is intended for application in arterial thrombosis indications, such as Acute Coronary Syndrome patients undergoing Percutaneous Coronary Intervention.  A clinical program in Open Heart Surgery [including coronary artery bypass grafting (CABG) and valve repair/replacement] is also under development.  REG2, Regado's second product candidate, consists of a subcutaneously administered depot formulation of pegnivacogin paired with the IV bolus formulation of anivamersen.  REG2 recently completed single escalating dose phase 1 clinical testing (the first successful subcutaneous application of an aptamer in humans) and is planned to be studied in a multiple escalating dose clinical trial in 2011.  It is intended for use in venous thrombosis indications such as venous thromboembolism (VTE) prophylaxis in patients undergoing abdominal surgery.  REG3, Regado's third program, consists of a specific GPVI inhibitor and its active control agent (RB571 and RB515, respectively).  REG3 is planned to enter phase 1 human clinical testing in 2011 and will be indicated for antiplatelet therapy.  Information pertaining to Regado's clinical programs may be obtained at

SOURCE Regado Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Regado Biosciences, Inc. to Present at the Sofinnova Japan Biopharma Partnering Conference in Tokyo, Japan
2. Regado Biosciences to Present at the Annual UBS Global Life Sciences Conference in New York City
3. Regado Biosciences, Inc. Presents Results of the RADAR Phase 2b Clinical Trial of its REG1 Anticoagulation System
4. Regado Biosciences to Present at the Needham & Companys 10th Annual Healthcare Conference in New York City
5. Regado Biosciences, Inc. Announces Presentation of the Results of the RADAR Phase 2b Clinical Trial of Its Anticoagulant System REG1 at the i2 Summit During the American College of Cardiology 2011 60th Annual Scientific Session & Expo in New Orleans
6. Regado Biosciences to Present at the 2011 RBC Capital Markets Healthcare Conference in New York City
7. Regado Biosciences, Inc. Introduces REG3, a Novel Aptamer-Based Inhibitor of Glycoprotein VI and its Matched Active Control Agent, at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
8. Regado Biosciences, Inc. Presents Pharmacokinetic and Pharmacodynamic (PK/PD) Substudy Results From its Phase 2b RADAR Trial at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
9. Regado Biosciences, Inc. Presents Two Abstracts on the Subcutaneous Depot Formulation of Pegnivacogin, a Nuclease-Stabilized RNA Aptamer, Direct Factor IXa Inhibitor and Part of the REG2 Anticoagulant System, at the American Heart Association (AHA)
10. Regado Biosciences to Present at the IMPACT 2010 Conference in Philadelphia, Pennsylvania
11. Regado Biosciences, Inc. Presents the First-In-Human Clinical Experience with REG2 at the American College of Chest Physicians (ACCP) Coagulation and Heart Disease Sessions in Vancouver, BC, Canada on November 2, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... 29, 2015 Research and ... "Pharmaceutical Packaging Market in North America 2015-2019" ... market in North America to ... 2014-2019. International regulations regarding safe drug ... which in turn fuels adoption of sustainable packaging. Various ...
(Date:7/6/2015)... DUBLIN , June 29, 2015 ... the addition of the "Urinary Slings Market in ... The analysts forecast the Urinary Slings market in ... percent over the period 2014-2019. This report covers ... Urinary Slings market in the US for the period ...
(Date:7/6/2015)... July 6, 2015 Moerae Matrix, a ... therapeutics that target inflammation and fibrosis, today announced ... PhD, as Chief Medical Officer. ... strategy and programs, which include a pipeline of ... fibrotic conditions.  Bill is an accomplished strategist and ...
Breaking Medicine Technology:North American Pharmaceutical Packaging Market 2015-2019 with Amcor, Bemis Healthcare Packaging, MeadWestvaco, Owens-Illinois & West Pharmaceutical Services Dominating 2North American Pharmaceutical Packaging Market 2015-2019 with Amcor, Bemis Healthcare Packaging, MeadWestvaco, Owens-Illinois & West Pharmaceutical Services Dominating 3United States Urinary Slings Market 2015-2019 - Vaginal Slings (TVT, TOT, and Single-incision) & Male Slings (Artificial Urinary Sphincters) 2Moerae Matrix, Inc. (Moerae) Appoints Bill Bradford, M.D., PhD, as Chief Medical Officer 2
... and LOS ANGELES, April 18, 2007,/PRNewswire-FirstCall/ -- ... studies, one identifying a functional,biomarker for its ... preclinical anti-tumor activity with its,Bruton's tyrosine kinase ... the American Association for Cancer Research (AACR),2007 ...
... Equivalent and Irradiated Tumor,Cells Increased Long-Term Survival ... a,Preclinical Model of Brain Cancer--, LOS ANGELES ... Peregrine Pharmaceuticals, Inc. , a,clinical stage biopharmaceutical ... of cancer and hepatitis C,virus (HCV) infection, ...
Cached Medicine Technology:Pharmacyclics Identifies Functional Biomarkers for its Novel HDAC,Inhibitor and Demonstrates Preclinical Anti-Tumor Activity with,Bruton's Tyrosine Kinase Inhibitors 2Pharmacyclics Identifies Functional Biomarkers for its Novel HDAC,Inhibitor and Demonstrates Preclinical Anti-Tumor Activity with,Bruton's Tyrosine Kinase Inhibitors 3Pharmacyclics Identifies Functional Biomarkers for its Novel HDAC,Inhibitor and Demonstrates Preclinical Anti-Tumor Activity with,Bruton's Tyrosine Kinase Inhibitors 4Pharmacyclics Identifies Functional Biomarkers for its Novel HDAC,Inhibitor and Demonstrates Preclinical Anti-Tumor Activity with,Bruton's Tyrosine Kinase Inhibitors 5Data Presented at AACR Meeting Show Peregrine's Bavituximab,Equivalent Can Generate Curative Immune Responses as Part of a,Vaccine-Like Regimen in Preclinical Models of Aggressive Brain,Cancer 2Data Presented at AACR Meeting Show Peregrine's Bavituximab,Equivalent Can Generate Curative Immune Responses as Part of a,Vaccine-Like Regimen in Preclinical Models of Aggressive Brain,Cancer 3Data Presented at AACR Meeting Show Peregrine's Bavituximab,Equivalent Can Generate Curative Immune Responses as Part of a,Vaccine-Like Regimen in Preclinical Models of Aggressive Brain,Cancer 4Data Presented at AACR Meeting Show Peregrine's Bavituximab,Equivalent Can Generate Curative Immune Responses as Part of a,Vaccine-Like Regimen in Preclinical Models of Aggressive Brain,Cancer 5Data Presented at AACR Meeting Show Peregrine's Bavituximab,Equivalent Can Generate Curative Immune Responses as Part of a,Vaccine-Like Regimen in Preclinical Models of Aggressive Brain,Cancer 6
(Date:7/6/2015)... ... July 06, 2015 , ... MD Now, the leading and ... The newly constructed urgent care center will serve residents and visitors in the Cutler ... being MD Now’s 22nd South Florida location, the new facility will be the fourth ...
(Date:7/6/2015)... ... July 06, 2015 , ... The School ... funds to support a three-year effort to reduce rates of diabetes and cardiovascular ... in partnership with the Morehouse School of Medicine’s Prevention Research Center and the ...
(Date:7/6/2015)... Pompano Beach, Florida (PRWEB) , ... July 06, ... ... call center solutions, announced today that Randstad Technologies selected Aspect Software Unified IP ... provider in the United States, selected Aspect Unified IP as its future call ...
(Date:7/6/2015)... (PRWEB) , ... July 06, 2015 , ... Thanks to ... Health and Hospice received the Music & Memory Certification for hospice patients and adult ... power of music not only to patients but also to their families and volunteers. ...
(Date:7/5/2015)... ... , ... City Sports, the Boston-based specialty sporting goods retailer, has renewed their ... triathletes this summer with ethos, the owner and operator of the Boston Triathlon. , ... p.m. at the North End Greenway. The event will help new triathletes prepare for ...
Breaking Medicine News(10 mins):Health News:MD Now Urgent Care Opens its Fourth Miami-Dade County Facility in Cutler Bay 2Health News:MD Now Urgent Care Opens its Fourth Miami-Dade County Facility in Cutler Bay 3Health News:Georgia State, Morehouse Partner To Tackle Diabetes, Heart Disease In Atlanta’s Minority Communities 2Health News:Aspect Software Unified IP, Hosted by Promero, Selected by Randstad Technologies 2Health News:Aspect Software Unified IP, Hosted by Promero, Selected by Randstad Technologies 3Health News:Music & Memory Program Brings Joy and Excitement to Hospice Patients 2Health News:Music & Memory Program Brings Joy and Excitement to Hospice Patients 3Health News:Music & Memory Program Brings Joy and Excitement to Hospice Patients 4Health News:Sporting Goods Retailer City Sports Renews Partnership with Boston Triathlon 2Health News:Sporting Goods Retailer City Sports Renews Partnership with Boston Triathlon 3
... try to emulate,others, lifestyles, adopt someone,s new fad ... in frustration and failure," writes Larry G.,Patten. "These ... own idea of great,health.", In "Champion Health" ... offering in his Champion Series of,self-improvement books, Patten ...
... see modest tie between displeasure, peripheral artery disease ... Sexual dissatisfaction in postmenopausal women isn,t associated with ... that sexual dysfunction in some men is predictive ... been examined in women. , In this study, ...
... Health Care Quality Act, Would Save Thousands of Lives,Billions ... top companies joined forces Wednesday, April 2, 2008, with ... "Wired for Health Care,Quality Act," a measure to bring ... To view the Multimedia News Release, go to:, ...
... /Xinhua-PRNewswire-FirstCall/ -- China,Nepstar Chain Drugstore Ltd. (NYSE: ... drugstore chain in China based on the number ... been awarded the,title of "Best Drugstore Chain of ... trade publication in the Drugstore industry in China., ...
... The undersigned,organizations from around the state are releasing ... candidates campaigning here now,to draw attention to Pennsylvania,s efforts ... HB 2098 and HB 2005., An Open Letter, ... Senator Obama:, Healthcare has been central to each ...
... /PRNewswire-FirstCall/ - Haemacure Corporation (TSX,: HAE), a ... protein products for commercialization,disclosed today the results ... on,the use of its proprietary lead product ... the formation of post-surgical adhesions., The ...
Cached Medicine News:Health News:'Champion Health': Learn How to Create a Unique, Personalized Health Plan That Works and Keeps Working 2Health News:Postmenopausal Women's Sexual Dissatisfaction Not Linked to Heart Troubles 2Health News:Video: Senators and CEOs Urge Passage of Health IT Bill Now 2Health News:Video: Senators and CEOs Urge Passage of Health IT Bill Now 3Health News:China Nepstar Chain Drugstore Awarded Prestigious Title of '2007 Best Drugstore Chain in China' by China Drugstore Magazine 2Health News:China Nepstar Chain Drugstore Awarded Prestigious Title of '2007 Best Drugstore Chain in China' by China Drugstore Magazine 3Health News:Open Letter to Presidential Candidates on State Health Care Reform 2Health News:Haemacure Discloses Positive Results of a preclinical study of its fibrin sealant in adhesion prevention and opens a new opportunity in a market with a significant unmet medical need 2Health News:Haemacure Discloses Positive Results of a preclinical study of its fibrin sealant in adhesion prevention and opens a new opportunity in a market with a significant unmet medical need 3
... The pharmaceutical subset of the ... 21 of the Code of ... and final rules published in ... updated regularly as released by ...
... measuring principle - Pupil Zone Imaging Method ... offers high accuracy and reliability in refraction ... measurement (3.3 mm) using a mire ring, ... 4 points, both of which offer reliable ...
The combination of new measuring principle - Pupil Zone Imaging Method - and unique technology - SLD - offers high accuracy and reliability in refraction measurement....
... The ISI Free-Standing upper extremity table ... and in-office procedures. This table features ... and an extra-durable, hour-glass shaped Lexan ... stable -- this table is our ...
Medicine Products: